Overview

Hyper-Thermia Enhanced Anti-tumor Efficacy of Trabectedin

Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
This trial compares trabectedin alone to trabectedin in combination with regional hyperthermia in patients with high-risk soft tissue sarcoma. The study is designed to demonstrate a significant benefit for sarcoma-therapy by adding regional hyperthermia.
Phase:
Phase 2
Details
Lead Sponsor:
Ludwig-Maximilians - University of Munich
Treatments:
Trabectedin